EHA 2024: Updates in the Treatment of CLL - Episode 20
Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.
Video content above is prompted by the following: